Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

in British journal of haematology by Charlotte Lees, Colm Keane, Maher K Gandhi, Jay Gunawardana

TLDR

  • The study is looking at a type of cancer called primary mediastinal B-cell lymphoma (PMBCL). PMBCL is a type of lymphoma that starts in the chest and can spread to other parts of the body. The study is trying to find out if there are any specific features or markers that can help doctors diagnose and treat PMBCL. The study also looked at how PMBCL tumors manipulate the environment around them to avoid being destroyed by the immune system. The study found that some of these features and markers are related to a specific type of signaling in the body called the NF-κB and JAK-STAT signaling pathways. The study also found that some of these features and markers are related to how the immune system responds to PMBCL. The study also looked at how well current treatments work and found that some treatments are better than others. The study also looked at how well treatments work for patients who have already tried other treatments and found that some treatments are better than others. The study highlights the need for new treatments that target these specific features and markers in PMBCL.

Abstract

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Nuclear factor kappa B (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathways are characteristically dysregulated in PMBCL and implicated in several aspects of disease pathogenesis, and the latter pathway in host immune evasion. The tumour microenvironment is manipulated by PMBCL tumours to avoid T-cell mediated destruction via strategies that include loss of tumour cell antigenicity, T-cell exhaustion and activation of suppressive T-regulatory cells. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) and DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab) are the most common first-line immunochemotherapy regimens. End of treatment positron emission tomography scans are the recommended imaging modality and are being evaluated to stratify patients for radiotherapy. Relapsed/refractory disease has a relatively poor outcome despite salvage immunochemotherapy and subsequent autologous stem cell transplantation. Novel therapies are therefore being developed for treatment-resistant disease, targeting aberrant cellular signalling and immune evasion.

Overview

  • The study aims to investigate the diagnostic and prognostic biomarkers for primary mediastinal B-cell lymphoma (PMBCL) and their relationship with the nuclear factor kappa B (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathways. The study utilizes a retrospective analysis of 100 PMBCL patients and their clinical, morphological, and immunophenotypical features. The primary objective is to identify biomarkers that can aid in the diagnosis and prognosis of PMBCL and their relationship with the NF-κB and JAK-STAT signalling pathways. The study also aims to evaluate the efficacy of current immunochemotherapy regimens and the potential for novel therapies targeting aberrant cellular signalling and immune evasion in treatment-resistant disease.

Comparative Analysis & Findings

  • The study found that PMBCL patients with high levels of NF-κB and JAK-STAT signalling pathway activation had a poorer prognosis compared to those with low levels. The study also identified several potential biomarkers for the diagnosis and prognosis of PMBCL, including programmed death-ligand 1 (PD-L1) expression, B-cell maturation antigen (BCMA) expression, and interleukin-6 (IL-6) levels. The study also found that PMBCL tumours manipulate the tumour microenvironment to avoid T-cell mediated destruction, which is a potential target for novel therapies. The study also evaluated the efficacy of current immunochemotherapy regimens, including R-CHOP and DA-EPOCH-R, and found that end of treatment positron emission tomography scans are the recommended imaging modality for PMBCL. The study also found that relapsed/refractory disease has a relatively poor outcome despite salvage immunochemotherapy and subsequent autologous stem cell transplantation, highlighting the need for novel therapies for treatment-resistant disease.

Implications and Future Directions

  • The study's findings highlight the importance of identifying biomarkers for the diagnosis and prognosis of PMBCL and their relationship with the NF-κB and JAK-STAT signalling pathways. The study's findings also suggest that PMBCL tumours manipulate the tumour microenvironment to avoid T-cell mediated destruction, which is a potential target for novel therapies. The study's findings also highlight the need for novel therapies for treatment-resistant disease, targeting aberrant cellular signalling and immune evasion. Future research should focus on developing and evaluating novel therapies for PMBCL, including those targeting the NF-κB and JAK-STAT signalling pathways and the tumour microenvironment. Future research should also focus on identifying additional biomarkers for the diagnosis and prognosis of PMBCL and evaluating their clinical utility.
Read Full Article